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Abstract: Current available methods for the clinical diagnosis of urinary tract infection (UTI) rely
on a urine dipstick test or culturing of pathogens. The dipstick test is rapid (available in 1–2 min),
but has a low positive predictive value, while culturing is time-consuming and delays diagnosis
(24–72 h between sample collection and pathogen identification). Due to this delay, broad-spectrum
antibiotics are often prescribed immediately. The over-prescription of antibiotics should be limited,
in order to prevent the development of antimicrobial resistance. As a result, there is a growing need
for alternative diagnostic tools. This paper reviews applications of chemical-analysis instruments,
such as gas chromatography–mass spectrometry (GC-MS), selected ion flow tube mass spectrometry
(SIFT-MS), ion mobility spectrometry (IMS), field asymmetric ion mobility spectrometry (FAIMS)
and electronic noses (eNoses) used for the diagnosis of UTI. These methods analyse volatile organic
compounds (VOCs) that emanate from the headspace of collected urine samples to identify the
bacterial pathogen and even determine the causative agent’s resistance to different antibiotics. There is
great potential for these technologies to gain wide-spread and routine use in clinical settings, since the
analysis can be automated, and test results can be available within minutes after sample collection.
This could significantly reduce the necessity to prescribe broad-spectrum antibiotics and allow the
faster and more effective use of narrow-spectrum antibiotics.
Keywords: urinary tract infection (UTI); electronic nose (eNose); volatile organic compound (VOC);
ion mobility spectrometry (IMS); gas chromatography–mass spectrometry (GC-MS); pattern recognition;
metabolite detection
1. Introduction
A urinary tract infection (UTI) is a microbial condition that can affect any part of the urinary system.
UTI is one of the most common bacterial infections with 150 million cases per year worldwide [1].
Adult women are 30 times more likely than men to develop a UTI [2]. Moreover, it is estimated
that 50–60% of women will experience at least one episode of UTI during their lifetime [1] with the
prevalence increasing with age (20% in women over 65 and overall population prevalence of 11%) [3,4].
UTI is a major global health burden, causing great distress as it is very uncomfortable and impedes the
patient’s ability to conduct day-to-day activities, such as work [3,5,6].
Current diagnostic methods rely heavily on a urine dipstick test, which offers a fast result (available
in 1–2 min) but has a low positive predictive value [7]. The accepted alternative method involves
culturing of the pathogens, which is more accurate and can inform clinicians on the type of bacteria
present. This is time-consuming and delays diagnosis (24–72 h between sample collection and pathogen
identification) [4]. Broad-spectrum antibiotics are therefore often prescribed immediately. However,
due to the delay, this practice is fuelling antimicrobial resistance. As a result, there is a growing need
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for alternative diagnostic tools. Recent advances in chemical-analysis technologies suggest that it
might be possible to ‘sniff out’ medical conditions, including bacterial infections, by analysing volatile
organic compounds (VOCs) emanating from the body and its waste.
The use of smell is possibly one of the earliest forms of medical diagnosis. Both ancient Chinese
and Greek physicians already recognised its diagnostic potential [8]. The father of modern medicine,
Hippocrates, used to put sputum samples on hot coals to generate an odour, then, based on the smell,
apply different treatments [9,10]. The basic concept of using odours to distinguish between disease
states has been supported by studies utilising the olfactory abilities of well-trained canines [10,11].
Numerous studies have demonstrated the ability of canines to smell cancers in the bladder [12],
lung [13], breast [14], prostate [15], and ovaries [16]. Despite their abilities, medical detection dogs are
very expensive to train and are impractical for routine clinical use.
It is now understood that odours mainly comprise of volatile organic compounds (VOCs),
which are carbon-based compounds, with high vapour pressure and low boiling points. VOCs are
produced within the body as a result of metabolic processes from the host, from microbial pathogens,
or resulting from a host response to pathological processes, such as infection or inflammation [17].
VOCs in urine are considered intermediate or end products of metabolic pathways [18]. These occur in
relatively higher concentrations than in other medium, such as breath—which makes them easier to
detect [19]. Recent studies have shown that characteristic urine VOC profiles can be linked to infectious
diseases [20,21] and different types of cancers [22–24]. These studies have demonstrated the potential
in utilising urine for diagnostic purposes.
The objective of this article is to review previous studies, focusing on the utility of urine headspace
VOC analysis as a diagnostic tool for UTI. This review first discusses UTIs and critically evaluates the
current diagnostic approach. Next, the paper reviews the analytical platforms that have been evaluated
as potential diagnostic tools for UTIs and summarises their characteristics. An extensive list of VOCs
associated with common UTI pathogens, either in cultures or urine samples, is then presented. Finally,
the developments needed to bring this approach into clinical practice are discussed.
2. Urinary Tract Infection
UTI can affect any part of the urinary system—kidneys (pyelonephritis), uterus, bladder (cystitis)
and urethra (urethritis). Most UTIs involve the lower urinary tract (bladder and urethra). The infection
can be caused by bacteria (Gram-negative and Gram-positive), as well as fungi. Furthermore,
70% of community-acquired UTIs and 50% of hospital-associated UTI are caused by UroPathogenic
Escherichia coli (UPEC) [25,26].
UTIs can be classified as complicated or uncomplicated. When cystitis or pyelonephritis occurs in
an otherwise healthy individual (premenopausal and non-pregnant women) and no abnormalities
are present in the urinary tract, the UTI is considered uncomplicated [27]. Immunocompromised
individuals, pregnant women, or patients with urinary tract abnormalities and UTI are classified as
complicated [28]. Abnormalities associated with complicated UTI include obstructions (tumours of
the urinary tract), instrumentation (indwelling urethral catheter) or metabolic abnormalities
(renal failure) [28]. If a UTI is not treated, the infection could spread from the kidneys into the
bloodstream, causing bacteraemia. If a systemic inflammatory response occurs, this could potentially
be followed by septicaemia, which can be fatal [1,29,30].
Even though UTI is rarely fatal, it produces high morbidity in vast numbers of patients. A patient
with cystitis often presents with urinary symptoms, which include dysuria (painful urination), urinary
frequency, urgency or haematuria (blood in urine) [1]. As the onset of UTI is sudden, rapid and painful,
it often incapacitates the person from their normal day-to-day activities, creating a feeling of guilt and
even depression [6]. Both physical and social functioning are negatively affected [3]. The direct impact
of UTI on health care relates to the cost of prescriptions, hospital expenses, travel, medical visits and
diagnosis—sometimes multiple urine cultures and imaging studies are required [31]. Overall, it results
in lowering the patient’s quality of life.
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Most commonly, UTI is initiated when a urinary pathogen from the bowel (sometimes from
the vagina—inoculation during sexual activity) enters the urinary tract via the urinary meatus [27].
In uncomplicated UTI, following UPEC, the most common pathogens are: Klebsiella pneumoniae, Staphylococcus
saprophyticus, Enterococcus faecalis, group B Streptococcus, Proteus mirabilis, Pseudomonas aeruginosa,
Staphylococcus aureus, and Candida spp [1]. In complicated UTI, the most prevalent agents of infection
after UPEC are: Enterococcus spp., K. pneumoniae, Candida spp., Staphylococcus aureus, P. mirabilis,
P. aeruginosa, and group B Streptococcus [1].
Broad-spectrum antibiotics are generally used for treating UTIs. However, with a better understanding
of the adverse impact this has on commensal bacteria present in the gut microbiome, this practice is
becoming of concern to healthcare professionals [32]. Moreover, the over-prescription of broad-spectrum
antibiotics could accelerate the development of antimicrobial resistance (AMR). It is estimated that,
by 2050, AMR will cause 10 million deaths globally (more than cancer—8.2 million) [33]. The threat
to patients is acquiring a multidrug-resistant agent, i.e., a microorganism that shows antimicrobial
resistance to at least one antimicrobial drug in three or more antimicrobial categories. In recent years,
the number of multidrug-resistant Gram-negative bacteria have increased and have been found to cause
UTIs [34]. Furthermore, antibiotics increase inflammation in the gut, which promotes the proliferation
of E. coli [35]. Since UPEC is usually found in the gastrointestinal tract, the surge in proliferation
increases the risk of subsequent UTI recurrence. As a result, broad-spectrum antibiotics can be used to
treat UTIs, but this also increases the risk of developing UTIs in future. UK NICE guidelines (National
Institute for Health and Care Excellence) recommends the use of narrow-spectrum agents for UTIs
whenever possible. This approach would be feasible if the pathogen could be rapidly identified.
3. Current Diagnostic Methods for Urinary Tract Infection
The diagnosis of UTI is currently based on culturing samples in a centralised clinical laboratory,
which results in a delay of 24–72 h from the moment the patient provides the sample to identifying the
bacteria. UTIs are usually defined by the urinary symptoms and the presence of at least 104 CFU/mL
in urine, though the cut-off point differs (NHS considers 105 CFU/mL as positive and the threshold
changes based on the presented symptoms) [25,36].
In the 1980s, the urine dipstick test was introduced to provide a fast, cheap and useful test in
diagnosing UTI. The dipstick test is a qualitative test, which assesses the presence of leukocyte esterase
and nitrate. Leukocyte esterase is a protein made by white blood cells and acts as a biomarker for those
immune cells. The presence of leukocytes in urine is indicative of a UTI. Nitrite is found in urine due to
the presence of nitrate reducing bacteria. Even though the dipstick is a cheap and fast test, it does not
narrow down the infection to a causative agent and may even miss some infections (e.g., non-nitrate
reducing bacteria). In a meta-analysis, the overall sensitivity of the urine dipstick test for leukocyte
esterase was 48–86%, with a specificity of 17–93%. For the nitrate dipstick test, the sensitivity was even
lower, with values between 45% and 60%, and a specificity of 85–98%. Overall, when combining both
tests, the sensitivity increases to 68–88% and specificity to 62–97% (one or both positive), depending on
the brand, cut-off standard, and population demographic [37]. A similar study found a sensitivity of
75% and specificity of 82% [38].
A rapid point-of-care test, which can accurately identify the pathogen, would have a positive
impact on UTI treatment, since the most effective course of antibiotics could be initiated immediately,
instead of prescribing broad-spectrum antibiotics. This would provide a significant benefit to the
patient in terms of saved time and avoided unnecessary pain, since they do not need to wait on culture
results. Furthermore, a standardised sensor would remove human error, making diagnosis faster,
easier, and objective.
4. Volatile Organic Compounds Detection Technology and Data Analysis
There are various competing technologies available for the analysis of VOCs in urine. The most
commonly used technique is gas chromatography, coupled with mass spectrometry (GC-MS) [18].
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Other methods include proton transfer reaction mass spectrometry (PTR-MS), ion mobility spectrometry
(IMS), selected ion flow tube mass spectrometry (SIFT-MS), field asymmetric ion mobility spectrometry
(FAIMS), gas chromatography flame ionisation detection (GC-FID), and electronic noses (eNoses),
which are made up of arrays of sensors, e.g., metal oxide (MOS), piezoelectric, or conducting polymer
(CP). A summary of the most common technologies, with a visual explanation of their working
principles, is shown in Figure 1.
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i r . Volatile organic compound (VOC) detection technologies for analysis of urinary tract infection
(UTI) urine samples; (To ) gas chromatography—mass spectrometry (GC-MS): the column of the
GC is represented in blue, resulting in compound separation based on their physical properties and
mass; (Middle) ion mobility spectrometry (IMS): the separation of compounds based on ion mobility
is represented by different groups of VOCs clustering together; (Bottom) electronic nose (eNose):
the eNose response is based on an array of different cross-sensitive gas sensors. A typical response is
shown for each method. VOCs are illustrated as green, blue, yellow and red circles.
In GC-MS, the GC part involves injecting samples into a separation column, where they are
transported by an inert carrier gas (usually helium or hydrogen). The gaseous mixture is separated
into its components based on the relative interactions between the analytes and the inner coating of the
column. Molecules with column interactions (e.g., lower boiling points or weight) exit the column
before higher interaction compounds. The MS is then used to detect exiting compounds. An ion
source is used to produce analyte ions. Electron impact ionisation is a commonly used technique,
which involves bombarding the analytes with a beam of electrons. This is followed by a mass
analyser, which sorts the fragment ions by their mass-to-charge ratio [39]. Lastly, the ions reach a
detector (e.g., electron multiplier), which measures the ionised mass fragments as an electrical signal.
GC-based technologies may also include two-dimensional GC-MS (GCxGC-MS) or combining GC
with a time-of-flight mass spectrometer (GC-TOF-MS). In a GC-TOF-MS system, once the sample has
passed through the GC column, the separated molecules are ionised and enter the TOF ‘flight box’.
TOF-MS works on the principle that when molecules are exposed to a pre-determined amount of
energy, larger, heavier ions will take longer than smaller, lighter ions to travel a set distance [40].
An emerging alternative to GC-MS is IMS. This technique uses a high electric field at ambient
pressure to separate different ions formed from the target analyte, based on differences in their
mobility. Drift-tube IMS uses the time taken for ionized molecules to traverse the tube. These ions are
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driven along the tube by a constant high-voltage electric field. Against the flow of ions, a buffer gas
(i.e., nitrogen) is used slow down the ions through collisions. This produces a time-dependent signal
that corresponds with ion mobility, with its drift time being a function of the number of collisions
and the ion interaction with the electric field. The drift-tube IMS method can be used in combination
with GC as a pre-separator. FAIMS is a different form of IMS, which reduces the drift tube length by
applying an alternating electric field across the ion path, changing the differential mobility of each ion.
FAIMS has been used to diagnose various diseases including colorectal cancer [41,42]. IMS systems
were originally used to detect chemical warfare agents, explosives, and illegal drugs, but have found
increasing applications in the medical domain. [43].
An eNose is an instrument that attempts to replicate the function of the biological olfactory system
by measuring VOCs as a whole, rather than identifying specific chemicals. It uses an array of broadly
tuned (cross-sensitive) gas sensors, which are used to measure a wide range of VOCs. As each sensor
in the array is different, the response between the odour and the sensor will be unique within the
array. This creates an odour “fingerprint” that can be learnt by some form of pattern recognition
technique. The eNose instrument types most frequently used for diagnostic applications in detecting
human disease include sensor arrays made up of metal oxide sensors (MOS), electrochemical sensors
(EC), conducting polymers (CP), carbon black polymer composite (CBPC), gold nanoparticles (GNP),
quartz crystal microbalance (QMB) sensors, and optical sensors [44].
MOS sensors are based on a reduction-oxidation reaction. In ‘clean’ air, oxygen is absorbed onto
the gas-sensitive layer of the sensor (e.g., tin oxide, SnO2). When exposed to a reducing or oxidising gas,
the oxygen reacts to the target gas that changes the conductivity of the sensitive layer [45]. EC sensors
are based on an electrochemical oxidation or reduction reaction, which occurs at the working electrode
(WE). In the presence of VOCs, the catalytic material reacts, and produces a current at WE. A counter
electrode (CE) keeps the sensor electrically neutral [46]. The operation of conducting polymer (CP) gas
sensors is based on a change in conductivity of the polymer film, when exposed to analyte vapours [47].
CBPC sensors operate based on swelling of the polymer upon exposure to target gases, which in turn
changes the resistance of the conducting film [48]. GNP sensors comprise of monolayer-capped gold
nanoparticle chemiresistive films [49]. When exposed to VOCs, they diffuse into the sensing film
and react with the capped ligands/functional groups, causing a volume shrinkage/expansion in the
nanomaterial film, resulting in a change in resistance [49,50]. QMB sensors use highly sensitive quartz
crystals for the measurement of the mass and viscosity of VOCs [51]. Changes in gravitational load
on the sensor and viscoelastic properties of the VOCs cause a frequency shift of the quartz crystal
resonator [52]. The optical sensor principle is based on absorption spectroscopy, using infrared (IR).
The amount of absorption depends on the gas concentration, at a wavelength related to a target
gas—selected using optical filters [53].
Each of these sensor technologies are associated with advantages and disadvantages. MOS sensors
are low cost and highly sensitive but have a limited sensing range and typically operate at higher
temperatures (between 300–500 ◦C) [54]. This high temperature requirement can result in increased
power consumption, while EC, CP, CBPC, GNP, and QMB sensors operate at ambient temperature and
therefore require lower power. CP and CBPC sensors are inexpensive and are highly sensitive to many
VOCs, but have a shorter operational life, compared to MOS sensors. They also demonstrate poor
repeatability and reproducibility due to the random nature of the polymer [55]. EC sensors have fast
response times, but are bulky in size and have limited sensitivity to simple or low molecular weight
gases [56]. GNP sensors are newer and combine gold nanoparticles with polymers or metal-oxides.
The polymer variants operate at room temperature but suffer from similar issues to CBPC sensors.
The metal-oxide composite variants operate at elevated temperature and have better selectivity
than normal MOS sensors, but are more challenging to fabricate [57,58]. QMB sensors have good
precision for a diverse range of VOCs, but require complex circuitry, have a poor signal-to-noise ratio,
and are sensitive to humidity and temperature [56]. Optical sensors have very fast response times,
high sensitivity and selectivity (especially to gases such as CO2 and CH4), but are more expensive,
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difficult to miniaturise and may require complex electrical circuits [56]. In order to take full advantage of
these characteristics, a combination of multiple sensor technologies can be deployed in a single device.
Recently, at the University of Warwick, the WOLF (Warwick olfaction) eNose was developed,
which contains 13 multi-technology sensors [59]. It was successfully used to distinguish between
colorectal cancer (CRC) and irritable bowel syndrome (IBS) patients [59]. While eNoses have been
emerging over the past decades as a new way to diagnose a variety of complex illnesses [60], they also
have downsides. Due to the nature of the sensors, they often drift over time and the response is
dependent on humidity and temperature [61]. As the sensors age, chemical deterioration can damage
the detecting surface of the sensor, which can cause issues with reproducibility. Without proper
maintenance, even if an identical sample is tested twice, the readings could be different. Approaches
to mitigate against these problems usually involve repeated sensor calibration [62].
In SIFT-MS, analytes are introduced into a flow tube and ionised with chosen precursor ions
(usually H3O+, NO+ or O2+). The resulting ions are quantified by mass filtering, using a quadrupole
MS to separate the ions based on their mass-to-charge ratio. SIFT-MS has the benefit of detecting
compounds and calculating the concentration from the ratio of product to precursor ions present in the
headspace of the sample in real-time, as well as not requiring calibration.
Other methods, such as nuclear magnetic resonance (NMR) spectroscopy and proton transfer
reaction-mass spectrometry (PTR-MS) have been used as chemical-detection technologies for VOC
identification in research, but also for diagnosis [60,63–66]. In NMR spectroscopy, the atomic nuclei are
excited by radio waves, resulting in nuclei orientation changes along the magnetic field. When excitation
is stopped, the return to the initial lower energy orientation causes energy emissions that can be detected.
This provides insight into the chemical composition of the sample [67]. In PTR-MS, VOCs undergo
proton-transfer reactions (with H3O+ ions) in a drift tube reactor and are measured by a quadrupole
MS (similar to SIFT-MS) [64]. PTR-MS offers real-time analysis and has been used to test breath and
urine samples for diagnosing diseases such as lung cancer and H. pylori infection [63,64,68].
Overall, eNoses and IMS have a lower purchase price, running and maintenance cost compared to
GC-MS, SIFT-MS and PTR-MS. In addition, eNoses and IMS systems can be made portable and used in
point-of-care applications, unlike other methods, which require laboratory settings. The disadvantages
of eNoses and, in most cases, IMS are that they cannot provide an insight into the chemistry of the
studied sample (e.g. chemical identification). Using GC-MS, more information about the organism
growth phase and metabolic pathway can be ascertained. However, for the diagnosis of UTI, eNoses and
IMS systems are still the most suitable candidates, since they are easy to use, portable, relatively
low-cost, and have methods which can be automated. Table 1 provides an overview and comparison
of the characteristics associated with commonly used VOC detection technologies.
Table 1. Characteristics of Volatile Organic Compound Detection Technologies.
Technology eNoses IMS GC-MS
CP MOS
Portability Good Good Good Poor
Cost Low Low Low High
Trained personnel No No No Yes
Sample throughput High High Medium Low
Speed Real-time Real-time Real-time Off-line
Metabolite detection No No No 1 Yes
Pattern recognition Yes Yes Yes Yes
Chemical insight No No Yes Yes
Sensor drift Yes Yes Minor Minor
1 Some IMS constructs allow for metabolite detection. Abbreviations: Electronic noses—eNoses; Ion mobility
spectrometry—IMS; Gas chromatography—ion mobility spectrometry—GC-IMS; Conducting polymer—CP;
Metal oxide sensors—MOS.
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Most applications of VOC analysis aim to discriminate between disease states. This may include
a simple case-control design (e.g., disease vs. controls) or a variety of investigated states and groups.
These applications predominantly rely on classification analysis to distinguish between groups and
to build and train models which can be used as a diagnostic tool. The classification methods most
commonly used in VOC analysis include principal component analysis (PCA), linear discriminant
analysis (LDA), partial least-square discriminant analysis (PLS-DA), and machine learning (ML)
algorithms. PCA is an unsupervised linear method, which reduces the dimensionality (number of
features, e.g., eNose sensor responses or GC-MS peaks) of the data by selecting a small number of
linearly uncorrelated principal components that explain the majority of the variation in the data [69].
LDA is a supervised linear method that tries to find a linear discriminant function to separate between
study groups [70]. PLS-DA is similar to LDA but attempts to maximise the co-variance between a
dummy class vector and the data matrix. PCA, LDA, and PLS-DA have been applied frequently for VOC
analysis studies, for both eNose and GC-MS data [71]. The disadvantage of these methods is that they
are most effective for investigating linear relationships between samples and classes (e.g., disease status).
However, they not well-equipped for representing non-linear relations that are likely to be present
in biological samples [72]. Non-linear statistical learning approaches, based on ML, are therefore
being increasingly used for the analysis of urine VOC datasets [24,73–76]. These methods can be
broadly categorised into three groups: tree-based methods (e.g., random forest—RF), neural networks,
and kernel-based methods (support vector machines—SVMs). The advantage of linear techniques is
that they are simple to interpret, require few parameters to be optimised, and are not computationally
demanding. The converse is true of ML techniques [70].
5. Detection of Urinary Tract Infection Using Volatile Organic Compounds
For urine analysis, the urine sample is usually transferred to a vial/container and then sealed.
The unoccupied area/air above the urine sample is known as the headspace and VOCs from the
urine desorb out of the liquid phase, into this air space and can be collected for analysis. In 1976,
the prospect of using headspace analysis for identifying bacteria became apparent when Hayward et al.
determined that Proteus species produce methyl mercaptan and dimethyl disulfide from methionine [77].
Furthermore, P. vulgaris, P. mirabilis, P. moraganii, and P. rettgeri were shown to produce benzaldehyde.
In the culture filtrate, phenylacetaldehyde and 2-phenylethanol are produced from phenylalanine.
Isobutyraldehyde and isobutanol are produced from valine and isovaleraldehyde, together with
isoamyl alcohol, from leucine. In uncomplemented media, isobutyraldehyde, isovaleraldehyde,
and isoamyl alcohol were detected. Moreover, it was shown that E. coli ferments lactose or arabinose
for energy and produces ethanol as a by-product.
In a paper from 1977, Hayward et al. tried to identify E. coli and Proteus species from cultures
and simulated urine infections with isolated bacteria, using gas-liquid chromatography. Ethanol was
suggested as an indicator for E. coli and dimethyl disulfide, together with methyl mercaptan, for Proteus
species [78]. Further work by Hayward and Jeavons involved testing 75 clinical urine samples. It was
found that ethanol is a biomarker for E. coli when grown in the presence of lactose and dimethyl
disulfide (as well as methyl mercaptan) for Proteus mirabilis and Proteus inconstans A [79]. The analysis
can be done in 3–5 h, after urine incubation. One drawback is the inability to tell apart Klebsiella aerogenes
from E. coli, since both species ferment lactose to ethanol. In a similar study, 49 strains of E. coli were
grown in media supplemented with arabinose [80]. It was confirmed that the bacteria produce ethanol
with a maximum concentration achieved after eight hours. As expected, the quantity of ethanol
production is directly proportional to the total number of bacteria present in the culture, thereby
providing a way to estimate the bacterial load in clinical samples. Following this, the possibility of
diagnosing UTIs instigated by another organism was investigated using a similar method. P. mirabilis
was found to produce dimethyl disulfide from methionine and it was once again confirmed that E. coli
produces ethanol from arabinose in culture [81]. The advantage of growing these bacteria in enriched
media, with arabinose and methionine, is that diagnosis is possible in just four hours. However, in the
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urine cultures containing K. aerogenes or K. ozaenae, ethanol was found in similar quantities as those
produced by E. coli showing the decreased discriminatory power of this method [79,81].
Discrimination between E. coli and Klebsiella species using the production of ethanol from lactose
(E. coli) or adonitol (Klebsiella) is also possible in less than six hours [82]. In addition, the following
VOCs: trimethylamine, ethanol and ethyl acetate, were associated with P. mirabilis, P. vulgaris, P. rettgeri,
and P. inconstans found via GC-MS [83]. During these experiments, it was confirmed that K. aerogenes
and E. coli produces ethanol as well as ethyl acetate. It was also shown that ethyl acetate was produced
by S. faecalis, N-propanol in E. coli’s headspace, and that ethyl acetate was found in P. inconstans B [83].
These developments have paved the way to show that VOC analysis of headspace can be used
to detect UTIs. This technique has three benefits: (1) it can provide chemical insight of the organism
tested, (2) it can indicate the metabolic pathway used by the bacteria, and (3) indicate its growth phase.
Unfortunately, this method has not gained wide-spread use in clinical settings. One reason for this
could be the complexity of analysing VOCs found in the headspace of bacterial cultures. These VOCs
often overlap between species, which makes discrimination very challenging.
Storer et al. used SIFT-MS to monitor 21 compounds, of eight different organisms: E. coli,
P. aeruginosa, S. aureus, P. vugaris, K. pneumoniae, E. faecalis, S. epidermidis, and C. albicans. It was shown
that this technology could identify a UTI in urine samples [84]. However, the urine was incubated
with the bacteria for six hours, allowing for compounds to build-up in the headspace. Furthermore,
the number of compounds measured did not facilitate discrimination between the different species.
In contrast, a paper by Thorn et al. showed that E. coli, S. aureus, P. mirabilis, Burkholderia cepacian,
and Streptococcus pyogenes could be distinguished by SIFT-MS. They monitored a set of 25 VOCs, out of
which 15 were the same as the aforementioned paper [85]. This highlights both the advantage and
disadvantage of this technology, i.e., the bacteria can indeed be identified, if sufficient data are available.
At the same time, prior knowledge of the combination of VOCs is required to discriminate between the
species. Furthermore, SIFT-MS has a high entry price point, costing even more than GC-MS.
Recently, GCxGC-TOF-MS methods were used to discover 28 new P. aeruginosa VOCs as well
as confirming 28 former VOCs [86]. This area of research seemed to gain further interest between
2017–2019, since a number of works relating to this topic were published [87–93]. Most research groups
used a metabolite detection approach: GC-MS [87,88], GCxGC-TOF-MS [93], and TD-GC-MS (GC-MS
coupled with a thermal desorption, TD, system) [91]. DeJong et al. identified E. coli in human urine
(simulated infection samples) using surface enhanced Raman spectroscopy [92].
As demonstrated, metabolite detection can be used to determine the pathogen present in urine
samples. Another application is determining its antibiotic resistance. Ion-molecule reaction-mass
spectrometry (IMR-MS) has been utilised to investigate whether E. coli was ampicillin resistant and S.
aureus oxacillin resistant [94]. This was achieved by using the concentration of methanethiol as a proxy
of growth in culture, in the presence or absence of antibiotics.
The various VOCs discovered to be produced by the most common UTI pathogens (in either
cultures or urine samples) are shown in Table 2. There are overlaps between the species, such as
ethanol, ethyl acetate, and methyl mercaptan, which are by-products of the bacterium metabolism.
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Table 2. Volatile Compounds of Different Urinary Tract Infection Pathogens.
Compound EC PM EF PA SA KP Compound EC PM EF PA SA KP
Alcohol Ester
Ethanol
√ √ √ √ √
ethyl acetate
√ √ √ √ √
Methanol
√
N-propylacetate
√ √
Propanol
√
n-butyl acetate
√
1-propanol
√
Ethyl phenylacetate
√
N-propanol
√
isopentyl acetate
√ √ √ √
2-(Methylthio)-ethanol
√ √ √ √
3-Methylbutyl 2-methylpropanoate
√
phenol
√ √
2-methylbutyl isobutyrate
√
Butanol
√ √
2-Phenyl ethyl acetate
√
1-butanol
√ √
Phenylethyl butyrate
√
2-butanol
√ √ √ √
methyl 2-methylbutyrate
√
Isobutanol
√ √ √ √
2-methylbutyl 2-methylbutyrate
√
2-methyl-1-butanol
√
methyl methacrylate
√ √
3-Methyl-1-butanol
√ √ √ √
ethyl 2-methylbutyrate
√
octanol
√
isoamyl butyrate
√ √
Decanol
√
amyl isovalerate
√
1-Decanol
√
ethyl isovalerate
√
dodecanol
√
ethyl formate
√
Benzyl Alcohol
√
ethyl butanoate
√ √
Isopentanol (isoamyl alcohol)
√ √ √ √
Propanoic acid 2-hydroxy-2-methyl-methyl ester
√
phenethyl alcohol
√ √
ethyl formate
√
ethylene glycol
√ √
Phenylacetic acid propylester
√
4-methylphenol
√ √
Ketone
2-methyl-1-propanol
√
acetone
√ √ √ √
acetol (hydroxyacetone)
√
Acetoin (3-hydroxybutanone)
√ √
2-phenylethyl alcohol
√
butanedione (diacetyl)
√
methylbutenol
√ √ √
Butanone
√ √ √
2-butanone
√ √ √
Aldehyde 2,3-butanedione
√ √ √ √ √
Acetaldehyde
√ √
2-heptanone
√ √ √ √ √
Benzaldehyde
√ √
4-heptanone
√
2-Heptenal
√ √
2-nonanone
√ √ √ √ √
(3-methylbutanal) Isovaleraldehyde
√ √ √ √ √
2-decanone
√
2-methylbutanal
√ √ √
2-hexanone
√
methylbutanal
√ √ √
2-Tridecanone
√
isobutyraldehyde
√
2-undecanone
√ √ √ √ √
3-(ethylthio)-propanal
√
2,3-Heptanedione
√
Propanal
√
2-pentanone
√ √ √
3-methyl-2-butenal
√
2-aminoacetophenone
√ √
2-ethylacrolein
√
3-octanone
√
(Z)-2-methyl-2-butenal
√
methyl isobutylketone
√
(E)-2-methyl-2-butenal
√
mercaptoacetone
√
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Compound EC PM EF PA SA KP Compound EC PM EF PA SA KP
Methacrolein
√
1-hydroxy-2-propanone
√
2-methylpropanal
√
Nonanal
√
1-methyl-4-(1-methylethenyl)cyclohexane
√ √ √ √
formaldehyde
√ √ √ √ √
Acids
Hydrocarbons isobutyric acid
√
Toluene
√ √ √ √ √
Butyric acid
√
1-Methyl-naphthalene
√
4-methylhexanoic acid
√
2-Methyl-naphthalene
√
Picolinic acid N-oxide
√
Isoprene
√ √
Isoamyl benzoate
√
2-Butene
√
Sulphur
(Z)-2-butene
√
methyl mercaptan (Methanethiol)
√ √ √ √ √ √
(E)-2-butene
√
dimethyl disulfide
√ √ √ √ √ √
Undecane
√ √
dimethyl sulfide
√ √ √ √
2,4-dimethylheptane
√ √ √ √
dimethyl trisulfide
√ √ √ √
3-methylheptane
√
Benzyl methyl sulfide
√
undecene
√
2-methoxy-5-methylthiophene
√
1-undecene
√
S-Methyl thiobenzoate
√
2-methyl-2-butene
√
2,4-dithiapentane
√
1,10-undecadiene
√
1-nonene
√
Chlorine
2-Nonene
√
Trichloromethane
√ √
1-decene
√
4-Chloro-1H-indole
√
1-dodecene
√
Butane
√
Inorganic
n-butane
√
ammonia
√ √ √ √
10-methyl-1-undecene
√
Hydrogen Sulfide
√ √ √
1,3-butadiene
√
2-methylpropene
√
Other
Propane
√
pyrazine derivative
√ √
2-Nonene, 3-methyl
√
benzene derivative
√ √ √ √ √
2,3,4-Trimethylhexane
√
phenol derivative
√ √ √
hexane
√
pentanone/toluene
√ √ √
2,3,3-trimethylpentane
√
Acetic acid
√ √ √
Nitrogen
Isovaleric acid
√
indole dimer
√
2-methylbutyric acid
√
ethylamine
√
Indole
√ √
Nitrogen 3-Methyl-1H-indole
√
methylpyrazine
√ √
Cadaverine
√ √
benzonitrile
√ √ √ √
putrescine
√
2,3,5-trimethylpyrazine
√
Acetonitrile
√ √ √
N-(Phenylmethylene)-methanamine
√
beta-phenylethylamine
√
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Table 2. Cont.
Compound EC PM EF PA SA KP Compound EC PM EF PA SA KP
N,N′-Dibenzylideneethylenediamine √
N-(Phenylmethylene)-1-propanamine
√
References [95] [96] [84] [95] [96] [83]
N-(Phenylmethylene)-1-butanamine
√ √
[97] [84] [93] [84] [84] [84]
n-nitrosodimethylamine
√
[83] [83] [93] [93] [96]
pyrrolidine
√
[80] [98] [99] [99] [93]
Isoamylamine
√
[81] [81] [100] [100] [100]
Isobutylamine
√
[93] [101] [102] [103] [104]
3-Methyl-N-(3-methylbutylidene)-1-butanamine
√
[99] [77] [105] [106]
Benzyl nitrile
√
[100] [91] [107] [91]
N-Butyl-benzenamine
√
[108] [100] [103] [104]
2-(3-Methylbutyl)-3,5-dimethylpyrazine
√ √
[105] [106]
3-Methyl-N-(2-phenylethylidene)-1-butanamine
√
[109] [104]
p-Pentylaniline
√
[110]
N-(1,1-Dimethylethyl)-benzamide
√
[91,104]
N-n-Butylphthalimide
√
4-methyl-quinazoline
√
Dimethylpyrazine
√
pyrrole
√
3-methylpyrrole
√
1-vinyl aziridine
√
Pyrimidine
√
2-Acetylthiazole
√
Trimethylamine
√ √ √
Abbreviations: EC—Escherichia coli, PM—Proteus mirabilis, EF—Enterococcus faecalis, PA—Pseudomonas aeruginosa, SA—Staphylococcus aureus, KP—Klebsiella pneumoniae.
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The same pathogens responsible for UTI can also cause infections in other parts of the body,
such as the lungs, blood, or burn wounds. The fact that VOCs identified in urine specimen culture,
or pure culture, overlap with VOCs found in the headspace of the same bacteria from different clinical
specimens confirms that the bacteria is being detected. For example, 2-aminoacetophenone is the
compound responsible for the grape-like odour of P. aeruginosa and was found from clinical isolates
from the Burn Unit of the University of Iowa Hospitals. Furthermore, 2,4-Dimethylquinazoline and
4-Mehtylquinazoline were also found [111]. In addition, SIFT-MS was used on cultures of P. aeruginosa
from cystic fibrosis patients [112]. Simulated blood infections and blood culture bottles with E. coli,
P. aeruginosa and S. aureus were analysed by SIFT-MS, confirming previously found products [113–115],
with antibiotic resistance of E. coli to gentamicin and S. aureus to flucloxacillin, determined by VOC
suppression in culture [113]. E. coli resistance to gentamicin was determined using SIFT-MS—after
22 h of incubation, the production of hydrogen sulfide from the bacteria was eliminated (acetic
acid, 2-aminoacetophenone, ethanol, methanethiol, pentanols, propanol, and dimethyl disulfide
were also inhibited). When S. aureus’s headspace was analysed, 2-aminoacetophenone, ethanol and
formaldehyde production were found to be inhibited by flucloxacillin [113]. GC-MS has been used
on infected sinus mucus with bacterial species including S. aureus and P. aeruginosa [103]. In the
lung of cystic fibrosis patients, colonized with P. aeruginosa, 2-aminoacetophenone was found by
GC-MS breath analysis, but also in the headspace of the cultured organisms [116]. The headspace
of E. coli, P. aeruginosa, K. pneumoniae, and S. aureus from inoculated artificial sputum medium or
nutrient broth was tested with GC-TOF-MS [117]. Similarly, GC-IMS has been deployed to analyse the
headspace of blood cultures containing E. coli, S. aureus and P. aeruginosa [118]. A study involving 210
samples of bronchoalveolar lavages found volatile fatty acids in the headspace of Candida alibicans,
Enterococcus faecalis, Pseudomonas aeruginosa, K. pneumoniae, Proteus species, S. aureus, and other
bacteria [119]. Using clinical blood cultures and reference strain bacterial blood cultures, volatile fatty
acids were detected in a number of UTI relevant pathogens [120]. IMR-MS was also used to distinguish
between Gram-negative and Gram-positive bacteria from positive blood culture samples, with some of
the bacteria also being responsible for UTI: S epidermidis (n = 87), S. aureus (n = 17), E. coli (n = 30),
and K. pneumoniae (n = 8) [121].
6. Electronic Nose and Ion Mobility Spectrometry Use
There have been a number of studies that utilised eNoses to detect UTI. In 2001, the Osmetech
Microbial Analyzer (OMA) polymer sensor array was used directly on 534 urine samples and
discriminated between infected from non-infected samples, at a cut-off of 105 CFU/mL, with a
sensitivity of 83.48% and specificity of 87.59% using principal component analysis (PCA) [122].
Despite these promising results, the drawback of this study is that it only provides information
about the infection status of the patient, without identifying the causative agent. The following year
(2002), a different eNose system (the Bloodhound BH114) was used to not only identify UTIs but
also the bacterial agent [123]. A limitation of this study was that samples were cultured for 4.5 or
five hours, making the sample processing time similar to the previously discussed GC-based work,
without providing chemical identification. A total of 45 samples were analysed, including 30 UTI
cases. Using genetic algorithms and back-propagation neural networks, discrimination between
E. coli, Proteus spp., and coagulase negative Staphylococcus spp. was possible with 98% prediction
rate (31 training samples and 14 tests with 13 out of 14 correctly identified) or 95% prediction rate
(26 training samples and 19 tests with 18 out of 19 recognised) depending on which neural network
was applied. Another study in 2008 by Kodogiannis et al. demonstrated that the Bloodhound BH114
can be used to discriminate the same species, this time, achieving 100% accuracy with four feature
extraction approaches (divergence, absorption, desorption, and area) [124].
Similarly, the Cyranose Sciences’ Cyranose 320 eNose was used in parallel with an Agilent
4440 Chemosensor mass spectrometer to discriminate between infected and healthy urine samples,
without any prior culturing [125]. One of the problems faced when using this setup is the amount of data
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generated in a single experiment. As such, the paper investigated different data reduction approaches
including multilayer perceptron, radial basis function (RBF) neural networks and autoregressive
exogeneous models. In the urine screening experiments, 189 sensor responses from the Cyranose 320
eNose were used, with an ARX (autoregressive exogenous type) model, to achieve an accuracy of 65%
with data from all 32 sensors and 67% using 19 sensors (most negatively correlating). Furthermore,
71% accuracy was achieved when that was coupled with normalising. The accuracy obtained using
another approach (RBF) was 50%, with correlation results of 65% and 80% with the Hybrid NARX
model (73% was achieved when sensor numbers were reduced) [125].
Further studies have been conducted since 2011 [84,85]. Sabeel et al. used the Cyranose 320 eNose
to analyse urine containing either bacteria (one sample) or mucus (six samples), compared to healthy
urine (two samples). The drawback of this study is the small sample size and that no data accuracy was
provided [126]. In a later study, the ChemPro 100i (a device combining a type of IMS with MOS gas
sensors) was used in a proof-of-principle study with 101 bacterial cultures from urine containing: E. coli,
S. saprophyticus, Klebsiella species as well as E. faecalis [127]. The ChemPro100i achieved a sensitivity
and specificity of 90% and 96%, respectively, (using linear discriminant analysis—LDA) to identify
the bacteria and 95% and 97%, respectively, to distinguish between healthy and infected samples
(using logistic regression) [127]. This study demonstrated that accurate discrimination between healthy
and infected urine is possible, when different bacteria is present, using pattern recognition techniques.
The main advantage of using ChemPro 100i for UTI diagnosis is that the device is portable (handheld),
thereby facilitating point-of-care use.
In a study by Ratiu et al., the ChemPro 100i was used to discriminate between three bacterial
species (E. coli, Bacillus subtilis and S. aureus) [91]. In more recent work by Adebiyi et al., a new eNose,
produced by IBM, called the Electronic Volatile Analyzer (EVA) was used to differentiate strains of
E. coli-inoculated urine. A key feature of the new eNose is that it is intended for internet-of-things
(IoT) applications. By using different statistical methods, various accuracies were achieved by the EVA
eNose with, on average, over 90%, and some with even 100% [90]. Overall, current developments in
pattern recognition devices suggest that it is possible to detect specific bacteria in the VOC headspace
of urine. Table 3 provides a summary of these developments.
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Table 3. Urinary Tract Infection and Pathogen Volatile Organic Compounds Detection.
Reference and Year Technology Number Culture for Headspace Analysis Experiment/Findings
Hayward et al. [77], 1977 Gas-liquid chromatograph 68 strains
Basal defined media with potassium lactate,
amino acids and salts. Nutrient Broth (Oxoid)
and MacConkey agar (Oxoid). Incubation
still/shaken (160 rpm) at 37 ◦C
Samples were mechanically shaken for 5 min at 37 ◦C followed by 3 min
incubation at 60 ◦C prior to analysis. It was found that Proteus species will
produce dimethyl disulfide and methyl mercaptan from L-methionine.
Hayward et al. [78], 1977 Gas-liquid chromatograph 14 bacterial species
Basal defined media with lactate, amino acids,
salts and vitamins cultured still at 37 ◦C or
yeast extract broth still/shaken at 160 rpm.
Proteus mirabilis produces dimethyl disulfide and methyl mercaptan when
cultured with L-methionine. E. coli produces ethanol from lactose. Detection of
E. coli and P. mirabilis in urine based on ethanol production was achieved in 5 h
(ethanol for E. coli methyl mercaptan for P. mirabilis) or 4 h (dimethyl disulfide
for P. mirabilis). Other bacteria tested for dimethyl disulfide, methyl mercaptan
or ethanol production were: C. freundii, E. cloacae, S. marcescens, K. aerogenes,
K, oxytoca, K. ozaenae, P. aeruginosa, S. aureus, S. epidermidis, S. marcescens and
S. faecalis. Samples were mechanically shaken for 5 min at 37 ◦C followed by
3 min incubation at 60 ◦C prior to analysis.
Coloe et al. [80], 1978 Gas-liquid chromatograph 49 strains
24 h, unshaken cultures. Media: arabinose,
amino acid mixture, salt mixture, pH 7.4,
nicotinic acid (0.5 mg) and calcium
pantothenate
39/49 clinical samples: urine—29, faeces—8, pus—1, sputum—1. E. coli H19
incubation resulted in ethanol production from arabinose (maximum
concentration after 8 h). For headspace analysis the mixture (culture fluid with
6 g of anhydrous K2CO3) was shaken at 160 rpm at 37 ◦C for 5 min and then
heated at 60 ◦C in a water bath for 5 min.
Coloe et al. [81], 1978 Gas-liquid chromatograph 122 urine samples
37 ◦C, 4 h shaking in 6 mL yeast-extract
peptone water enriched with arabinose and
methionine
94 samples from UTI suspected patients, 28 uninfected controls. Results
available in 4 h. E. coli produces ethanol from arabinose and P. mirabilis
dimethyl disulfide from methionine.
Hayward et al. [128], 1983 Gas-liquid chromatograph 382 urine samples
Methionine yeast-extract peptone medium
supplemented with arabinose incubated
for 3.5 h.
E. coli, Klebsiella, Citrobacter and Proteus species. Ethanol production from
lactose/arabinose of E. coli and methyl mercaptan from methionine of
Proteus spp (methyl mercaptan oxidizes to dimethyl disulfide). No false
positives and false negatives. Liquid was heated to 60 ◦C for headspace
sampling.
Manja et al. [82], 1983 Gas-chromatography 96 urine samples
E. coli detection M-9 salt mixture,
M-9L medium at 44 ◦C, 5 h. Klebsiella detection
M-9A medium (M-9L with lactose replaced by
adonitol and carbenicillin), 37 ◦C.
16 cases caused by E coli, 4 by Klebsiella and 2 were missed by GC. Ethanol
presence indicates the bacteria present (in M-9L of E. coli and in M-9A of
Klebsiella). All samples cultured in both media.
Davies et al. [83], 1984 Gas-liquid chromatograph 125 strains
Urine culture, 37 ◦C, 3.5 h, unshaken, media
made of yeast-extract peptone
medium concentrate.
For headspace samples—liquid temperature 60 ◦C for 5 min. Production of
trimethylamine from acetylcholine biomarker for P. mirabilis, P. vulgaris,
P. retgeri, P. inconstants A (not in P. morganii and P. inconstans B). Same species
also produced ethanol and ethyl acetate. Ethanol production from arabinose
was found in E. coli, K. aerogenes, all strains of S. faecalis. Ethyl acetate
produced by K. aerogenes, S. faecalis, E. coli (with n-propanol) and P. inconstans
B. No VOCs found P. morganii, S. epidermidis, S. aureus, P. aeruginosa.
Aathithan et al. [122], 2001
Osmetech Microbial
Analyzer (OMA) Polymer
sensor array
534 clinical samples No
Sensitivity of 83.48%, specificity of 87.59% (infection defined
as >1 × 105 CFU/mL). 72.3% sensitivity and 89.38% Specificity at 104 CFU/mL
cut-off. Threshold PCA values were set using control experiments with
reconstituted urine specimens inoculated with bacteria (4 cultures for each
organism—result average 4 replicates)—4 blanks for each organism.
Organisms: E. coli, E. faecalis, S. aureus, Klebsiella spp., S. saprophyticus
and P. mirabilis
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Reference and Year Technology Number Culture for Headspace Analysis Experiment/Findings
Pavlou et al. [123], 2002 Bloodhound BH114 25 and 45 urine samples
4.5 h incubation in enhanced media at 37 ◦C.
Media included: 60% brain heart infusion
broth, 40% cooked meat broth.
37 ◦C water bath for VOC sampling. First experiment: 20 out of 25 samples
UTI confirmed—9 E. coli, 5 P. mirabilis, 6 mixed infection of gram positive cocci
and Proteus species, 5 normal urine samples. Genetic Algorithms,
Back-Propagation Neural Networks (GA-NN) used—100% prediction on the
training set, the 9 samples not used for training were successfully identified.
Second experiment: 30 out of 45 samples UTI—13 E.coli, 9 Proteus. spp,
8 coagulase negative Staphylococcus species. First NN 98% prediction rate,
13/14 unknown samples identified correctly. Second NN 95% prediction
rate—18/19 unknown identified.
Yates et al. [125], 2005
Cyranose 320 electronic
nose and Agilent
4440 Chemosensor
189 Sensor Responses for
Urine (Cyranose 320) No
Data reduction and optimisation using non-linear model with a kernel width
parameter achieved 80% accuracy. Different statistical methods were used
accuracy attained: ARX model 65%, 67% (using data from 19/32 sensors),
71% using the most negatively correlated sensor; RBF—50%, using correlation
results 65%, Hybrid NARX model—80%. (73% when sensor number
was reduced).
Yates et al. [129], 2005 Agilent 4440
28 and 40 samples for
S. aureus. 32 data points
for E. coli
Yes
Agilent 4440 was used along with a pattern recognition algorithm (radial basis
function network) to distinguish between methicillin resistant and susceptible
S. aureus (100% accuracy obtained) and identify the growth phase of E. coli
(68.75% and 81.25% accuracy)—however the ones missed were misclassified
by one growth stage.
Kodogiannis et al.
[124], 2008 Bloodhound BH114 45 urine samples
Culture with Volatile generating kit,
5 h incubation at 37 ◦C
Headspace sample—37 ◦C water bath. 45 samples, 30 UTI (confirmed by
microscopy + culture)—13 E. coli, 9 Proteus spp,
8 coagulase—Staphylococcus spp. 31 samples used for training, 14 for
validation. Averaging the output of 4 feature-based networks (Divergence,
Absorption, Desorption, Area) the overall accuracy was 100%.
Bruins et al. [130], 2009 MonoNose 52 strains
BD-BACTEC™–Plus-Anaerobic/FMedium
with the addition of 0.1 mM FeCl3 for
measurements. Other commercially available
culture broths with different chemicals added
were also tested
104 measurements taken. Bacterial species tested: Escherichia coli,
Proteus mirabilis, Enterococcus faecalis, Pseudomonas aeruginosa,
Klebsiella pneumoniae, Staphylococcus aureus, Klebsiella oxytoca,
Enterobacter cloacae, Clostridium difficile and Salmonella enteriditis,
Salmonella typhimurium. Specificity varied with the organism tested—between
67% and 100%.
Storer et al. [84], 2011 SIFT-MS 90 (10 replicate samples foreach microbe) Inoculation of sterile urine for 6 h.
10 samples of inoculated urine for each pathogen: E. coli, Proteus vulgaris,
P. aeruginosa, S. aureus, S. epidermidis, K. pneumoniae, E. faecalis,
or Candida albicans. Presents a table with mean concentration of different
VOCs in the urine headspace.
Thorn et al. [85], 2011 SIFT-MS 11 strains (66—3 repeats foreach strain at 5 h and 24 h)
Bacterial plate cultures (20–24 h after
inoculation) were emulsified in 5 mL of 1%
tryptone-0.5% yeast extract broth, incubated at
37 ◦C, orbital shaking, 200 rpm, 24 h.
P. aeruginosa, S. aureus, E. coli, P. mirabilis, Burkholderia cepacian, S. pyogenes and
E. faecalis were studied. Control media sampling was also used (n = 36).
Table with the different VOCs presented and discrimination between species
is possible.
Wiesner et al. [94], 2011 IMR-MS 4 strains Liquid cultures in Muller-Hinton mediumshaken at 200 rpm and 37 ◦C
Antibiotic sensitive/resistant bacteria strain identification. Two strains of
E. Coli (one sensitive and one ampicillin resistant) and two S. aureus strains
(oxacillin sensitive/resistant) were used.
Bean et al. [86], 2012 GCxGC-TOF-MS 2 PA14 cultures and oneLB-Lennox blank 24 h culture at 37
◦C in lysogeny broth, Lennox
Discovered 28 new volatiles for P. aeruginosa PA14, 56 compounds in total.
Samples heated and stirred for 10 min at 50 ◦C. Solid-phase microextraction
SPME was used for headspace sampling PA14 strains.
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Jünger et al. [100], 2012 MCC-IMS 15 human pathogens 24 h at 37 ◦C on Columbia sheep blood agar.
Detection of VOC for E. coli, P. aeruginosa, P. mirabilis, K. pneumoniae, S. aureus,
S. epidermidis and other species using MCC-IMS in negative and positive ion
mode as well as GC/MS for confirmation.
Sabeel et al. [126], 2013 Cyranose 320 13 urine samples, selected 9 No
Cyranose 320 was introduced in 2 mL of urine 10 times for each of the
13 samples. PCA was used for analysis (first component explained 97.087% of
the variation). 9 samples were selected and classified as healthy (2),
containing bacteria (1), containing mucus (9)—UTI marker.
Roine et al. [127], 2014 ChemPro 100i, EnvironicsInc., Mikkeli, Finland
101 Cultures from
clinical samples
Cysteine lactose electrolytedeficient
(CLED) medium
Pathogens: E. Coli, S. saprophyticus, Klebsiella spp, E. faecalis. Samples
introduced in 36 ◦C water bath for 15 min prior to headspace analysis.
LDA and LR were used. Infected/non-infected discrimination LR—95%
sensitivity, 97% specificity; LDA—90% sensitivity, 96% specificity.
Bacterial discrimination 95% sensitivity 96% specificity LDA.
Validation method leave one out (LOOCV).
Boots et al. [104], 2014 GC-MS 200 (40 cultures foreach bacteria)
Overnight culture, 37 ◦C, blood agar plates.
Bacteria transferred to sterile brain heart
infusion broth for 4 h, agitated at 37 ◦C.
4 bacteria studied: P. aeruginosa, S. aureus, E. coli, K. pneumoniae. After the
overnight incubation the flasks were flushed with high-grade nitrogen
(3000 mL over 15 min). Identification of the species is possible as well as
methicillin-susceptible/resistant S. aureus strains.
Karami et al. [87], 2017 GC-MS 18 (2 medium used,3 time points, 3 organisms)
24 h in nutrient agar, subcultured at 37 ◦C in
two different broth medium—Muller Hinton
Broth and tryptic soy broth.
Identifying VOCs of E. coli, Candida albicans, S. aureus from cultures.
For headspace extraction cultures placed on a magnetic stirrer hotplate at
70 ◦C. Headspace extracted using SPME at 2, 4 and 24 h.
Ratiu et al. [91], 2017
ChemPro-100i (Environics
Oy, Finland)and TD-GC-MS
(for confirmation)
90 (3 replicates at
3 time points for each of the
10 cultures) and
30 for confirmation
Agar growth medium, 30 ◦C for B. subtilis and
S. aureus and 37 ◦C for E. coli
540 headspace samples were analysed (270 from bacteria and 270 blanks with
medium only). Discrimination between blanks and culture, the three species:
E. coli, Bacillus subtilis and S. aureus and the different time points (24, 48 and
72 h) was possible. A list of VOC identified with TD-GC-MS is also shown.
DeJong et al. [92], 2017 Surface enhancedRaman spectroscopy 3 Strains
Liquid Culture in Tryptic Soy Broth
Soybean-Casein Digest medium for 16 h at
37 ◦C transferred to agar-coated plates (Tryptic
Soy Agar Soybean-casein Digest).
SERS substrate was added.
The technique was applied to both cultures and simulated urine and blood
infections with discrimination possible after 16 h.
Rees et al. [93], 2018 GCxGC-TOF-MS 100 clinical isolates(blood/urine)
37 ◦C 200 rpm shaking overnight in Difco
Mueller-Hinston Broth (pre-culture) and 1:1000
same conditions for 12 h.
Prior to headspace analysis: 60 min at 37 ◦C, 200 rpm. Discrimination between
the most common infectious pathogens in blood and urine (E. coli,
Klebsiella species, P. aeruginosa, P. mirabilis, S. aureus, coagulase-negative
Staphylococcus, Acinetobacter species, Candida species, Enterobacter spp,
Enterococcus spp,.) was possible with a 95% accuracy using machine learning
(random forest) on 203 VOCs or 96% accuracy with 811 VOCs.
Smart et al. [89], 2019 TD-GC-MS 86 chromatograms,18 bacterial isolates
Overnight cultures, shaking at 180 rpm, 37 ◦C.
Subcultures grown for 3 h. Antibiotics
(cephalexin or ciprofloxacin) added after 2.5 h.
Bacteria: E. coli, K. pneumoniae, P. aeruginosa. Cultures grown in the presence of
cephalexin or ciprofloxacin before headspace analysis. Difference in VOC
profile was found between resistant and sensitive bacteria
Adebiyi et al. [90], 2019 IBM ElectronicVolatile Analyzer - 5-day culture in normal human urine at 37
◦C
Concentration of bacteria 1 × 109 CFU/mL. Incubated at 37 ◦C during
sampling. Different models (LR, SVM, RF, MLP) had different accuracy
(overall, 90%> and some had 100%)
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7. Discussion and Conclusions
UTI diagnosis has not changed for over 10 years and is not reflective of the currently available
methods and technologies. There is a clear need for a more accurate and rapid test, which is economically
feasible. Several research teams across the world are working on better ways to diagnose UTI in the
pursuit of the £8 m Longitude prize [131], an inducement prize contest by the UK-based charity NESTA
(National Endowment for Science, Technology and the Arts), incentivising the development of an
affordable, accurate, and fast point-of-care test for bacterial infection. This competition highlights both
the clinical demand for a new diagnostic tool and the growing research interest in the field.
There are several challenges associated with UTI diagnosis based on VOC analysis. While GC-MS
is considered the gold standard [132], this method is expensive, time-consuming and requires
highly-trained operators [133]. This also applies to other technologies, such as PTR-MS and SIFT-MS.
Most analytical platforms are not portable and therefore unsuitable for point-of-care applications. As a
result, urine samples need to be stored and transported from a clinical to a laboratory setting. Thereafter,
the urine sample often still has to be cultured (3.5–6 h). Further delays might be incurred between
generating results and reporting these to the clinician. Even once the sample has been analysed and
results are available, they are unlikely to be definitive, since VOCs are not always specific to a single
species. Some of these delays could be reduced by utilising eNose and/or IMS technologies, which are
suitable for direct analysis and can be used in a clinical setting. Other challenges associated with urine
VOC analysis are more fundamental. While urine analysis is the third major diagnostic screening test in
clinical laboratories, there is a lack of well-established and standardised methods regarding procedures
for collection, transportation, sample preparation and analysis [134]. During sample collection, patients
suspected for UTI are instructed to deliver a mid-stream urine (MSU) sample, by voiding firstly
into the toilet and secondly into a urine container. MSU samples are associated with significantly
higher bacterial levels than first-voided urine samples [135]. However, instructing a patient in MSU
collection can be time-consuming, challenging, and can introduce bias due to incorrectly collected
samples [136]. In addition to this, urine is susceptible to other confounding factors, such as dietary
intake, diuresis and exercise [137], as well as intake of prescription and non-prescription medication
and supplements [138]. Further difficulties are experienced during sample storage and transport.
Once the sample has been provided, it is essential for the sample to be frozen immediately, or at
least chilled. If the sample is left at room temperature beyond four hours before analysis, it may lead
to increased numbers of colony forming units (CFU) being interpreted as significant growth [136].
The samples also need to remain frozen during transport, which can impose logistical challenges for
both in-house and external sample transportation. A common solution to this is using dry ice, since it
has little effect on the samples for short transport periods [139]. The age of the sample should also
be considered [140]. Improper storage can lower the quality/performance of the urinary test [137].
In regard to sample preparation, various methods have been used to defrost samples. For example,
frozen samples might be stored at –80 ◦C and thawed at room temperature [141] or stored at –20 ◦C
and defrosted by immersing the vial in a water bath at 60 ◦C for 30 s [24]. Once the samples have been
defrosted, an aliquot of the sample is transferred into a vial. The analysed urine volume, per sample,
varies significantly across urine VOC studies, e.g., 0.75–8 mL [24,42,134,142]. If headspace analysis is
to be performed, the temperature of the sample is commonly elevated, to increase the sample vapour
pressure [143]. The duration and temperatures for this procedure vary across studies, e.g., 5–20 min
and 37–90 ◦C [42,144–146]. Lastly, while urine constitutes a highly complex and rich source of analytes,
headspace gas samples are unlikely to represent the full metabolite content of the medium. Method
development studies are therefore necessary to determine what procedures should be applied in order
to demonstrate the full potential of urine analysis for UTI diagnosis. Some challenges associated with
sample preparation and analysis have been improved through the use of auto-samplers, which have
enhanced the accuracy, repeatability, and productivity of urine analysis [137]. Optimised sampling and
analysis conditions for VOCs in urine headspace analysis should be investigated, as has been done
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for faecal samples [147]. This could significantly improve the clinical applicability of such methods,
in order to gain wide-spread use.
Despite the challenges, there are promising developments in the field of VOC analysis,
which indicate that this method has great potential to aid in the diagnosis of bacterial infection
in the future. The continuous drive for miniaturisation, portability, high-throughput and rapid analysis
is likely to produce a wide range of eNose and IMS designs which will offer great potential for a large
diversity of detection capabilities [148–150]. Moreover, as sensing technologies continue to advance,
a greater number of VOCs are likely to be detectable at lower concentrations [151]. The progress that
has been made in recent decades was illustrated in a meta-analysis, using machine learning on the
VOCs emitted by human microbial pathogens, extracted from papers published between 1977 and 2016.
The analysis showed that a set of 18 VOCs was sufficient to distinguish between 11 different infectious
agents, with an accuracy of 77% [152]. This suggests that the fundamental potential of using VOCs for
diagnosing bacterial infections has been successfully demonstrated. Further work is required to build
an extensive library of reliable VOC profiles, across different analytical platforms, which correspond
with UTI pathogens.
Some of the papers presented in this review cultured the sample/pathogens for a short period of
time. The use of direct analysis is associated with decreased sensitivity and specificity, since urine
varies drastically across individuals and even in the same person at different collection times (affected
by digestion of food, level of hydration and lifestyle [153–156]). However, even if the specificity and
sensitivity were to be decreased by 10–15%, these results would be comparable to the urine dipstick
test results, while providing crucial insight for the patient, since a targeted course of antibiotics could
be started immediately.
Following GC-MS methods, eNose and IMS technologies were evaluated for the diagnosis of
UTI. A common criticism of eNose and IMS technology is that they are unable to determine the
identity and concentration of individual VOCs, except for combined-technology instruments [60].
It has therefore been argued that this “black box” approach relies too heavily on pattern-recognition
algorithms [157]. Moreover, this method cannot yield a targeted VOC biomarker test for the diagnosis
of a particular condition or disease [158]. In this case, it is true that the eNose approach cannot
identify unique biomarkers for UTI. However, it should be noted that unique biomarkers do not
necessarily exist for individual UTI pathogens and that even if they did, they would be included as
a constituent of the overall pattern analysed by the algorithms. Furthermore, as indicated in this
review, pattern recognition has already demonstrated potential in determining the status of a sample
and recognised the relevant pathogen, without VOC identification. Another disadvantage associated
with eNoses is that, compared to classic culture, there is a lack of antibiotic resistance data. In future,
it may be possible to use eNoses on urine samples, with antibiotics added to them for a period of time,
to identify if a strain is susceptible or resistant. This information could drastically reduce the test time,
from the current standard of 24–72 h. If this is not feasible, local antibiotic resistance profiles and data
from clinical laboratories could be used to make predictions and recommendations for appropriate
treatments, once a pathogen has been identified in a urine sample. Moreover, the classification of
growth phase is possible and this can be used to calibrate the antibiotic dosage for treatment [129].
For VOC detection of UTIs to become routine in clinical use, a number of hurdles need to be
overcome. For example, more information regarding bacterial VOCs and data analysis models are
required. Moreover, clinical staff need to be educated about VOC urine headspace analysis, taught how
to interpret results and receive training on how to use the relevant equipment. An advantage of eNoses
and IMS systems is that they are relatively user-friendly. While eNoses do not recognise specific
VOCs, the sensors can be chosen to respond to specific chemical classes, which could increase the
accuracy of detection. This emphasises that some prior information regarding the VOCs of the urinary
pathogens is required, even for eNose analysis. One of the advantages of eNoses is also considered a
drawback for expanding the use of the technology—the versatility of devices makes it challenging
to establish a standard. Since research groups all over the world are developing different types of
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eNoses (MOS, QMB, or CP-based), it is unclear which one should be routinely used for UTI VOC
detection. A standard, commercially available, and CE-marked device would increase the probability
of wide-spread use by clinics and laboratories. Currently, the hardware used for detection, as well
as the software required for data analysis, is advanced enough to identify infected urine samples,
the pathogen and possibly its susceptibility to antibiotics. Since eNoses can be used in point-of-care
applications (e.g, bedside testing), with automated analysis and delivering results minutes after sample
collection, they have significant potential to serve as a clinical diagnostic tool for UTI. Furthermore,
the information provided by eNoses is objective and less prone to contamination during collection or
handling steps.
One of the key challenges associated with diagnosing UTI is that symptoms may overlap with
other conditions, such as haematuria—one of the most common signs of bladder cancer. In addition,
patients with asymptomatic bacteriuria may not benefit from treatment. However, distinguishing it
from UTI is often subjective, as what is classified as asymptomatic could be problematic when patients
with catheters or defects of the bladder (neurological or anatomical) are taken into consideration [25].
Catheters are a risk factor for UTI and catheter-associated urinary tract infection (CAUTI) is the
most common nosocomial infection worldwide [159]. This highlights the need for an accurate and
objective test. Further investigations are necessary to analyse whether VOC analysis could be used for
this application.
There are also other potential applications. For example, during pregnancy, a patient with
UTI can show no symptoms, i.e., the usual signs, such as pain and burning sensation, might be
absent. Cases of UTIs during pregnancy, even when asymptomatic, have been linked with preterm
delivery, intrauterine growth retardation, low birth weight, maternal hypertension, pre-eclampsia,
and anaemia [160]. The application of eNoses would be optimal for the routine testing of urine,
e.g., during antenatal appointments. This could provide an effective method of detecting asymptomatic
UTI during pregnancy.
Currently, the aim of deploying these technologies is not to replace the existing methods. Instead,
they are intended to complement the diagnostic process, by aiding clinicians and medics to make better
and faster decisions. The recent developments in technology, making the devices portable, accessible
for point-of-care, automation of data analysis, and overall ease of use, facilitates VOC detection for
routine clinical testing. Both metabolite detection and sensor-based techniques, together with pattern
recognition, provide a powerful tool for diagnosis. Further studies are required to investigate the
ability of eNoses to distinguish between resistant and susceptible bacterial strains. All medical devices
must go through clinical trials. As such, eNoses need to be registered, verified, and validated before
they can be accepted for routine clinical use.
8. Methods
An electronic search was performed using GoogleScholar and PubMed databases. The search terms
volatile organic compounds (VOCs), urinary tract infection (UTI), microbial, pathogen, and bacteria
were used in combination with the Boolean operators AND and OR. Additional searches were conducted
including common bacterial pathogens (e.g., UroPathogenic Escherichia coli and Klebsiella pneumoniae)
and analytical platforms (e.g., electronic nose (eNose) and gas chromatography mass spectrometry
(GC-MS)). Articles were selected for full-text examination based on the relevance of the title and
abstract. In the initial screening 65 articles were selected, further searches and references in the initial
articles resulted in selecting another 79 articles for full-text examination. From the investigated articles,
45 were included in this review, and 27 of those are incorporated in Table 3. Compounds found in
the literature (23 articles) are summarised in Table 2, divided by chemical classification (compounds
were only included once in the most relevant category). Nine articles that analysed pathogens isolated
from a different location (lungs/blood) or grown in blood culture were also included to illustrate that
the same VOCs are bacteria-related rather than location/media dependent. Either of the following
criteria had to be met in order to be included in the review: (1) VOC analysis was used to discriminate
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infected urine samples (clinical or simulated) or (2) VOCs were used to examine a pathogen that could
cause UTIs. Multiple publications of the same data were excluded.
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